OR WAIT 15 SECS
The company will showcase its gelatins for advanced pharmaceutical and biomedical applications at CPhI Worldwide on Oct. 9–11, 2018 in Madrid, Spain.
Rousselot, a global producer of gelatin and collagen peptides, will showcase its portfolio of premium gelatins for advanced pharma and biomedical applications at this year’s CPhI Worldwide.
At bioLIVE stand #12B13, the company will present its medical-grade purified gelatin range, X-Pure, for regenerative medicine applications. The company will also run a number of expert-led talks throughout the show on the effects of endotoxin. From its nutraceutical product portfolio, Rousselot will present its recently launched Peptan IIm, a hydrolyzed collagen type II matrix that specifically targets joint health, at a lunch brief and partnering sessions in a dedicated meeting space.
Rousselot will debut its low-endotoxin X-Pure range for the European market at its bioLIVE booth. Advanced gelatins with low endotoxin levels are needed for demanding medical applications including hemostatic medical devices, parenteral formulations, and regenerative medicine applications, the company reports. With endotoxin levels below 100, 20, or 10 endotoxin units per gram (EU/g) or even below limulus amoebocyte lysate (LAL) analysis detection limits, the X-Pure range offers important levels of safety for these in-body medical applications.
For regenerative medicine, in particular, Rousselot has developed five X-Pure gelatins to precisely match the needs of diverse final medical applications. The five gelatin grades come with different viscosities, gel strengths, and endotoxin levels and bring significant technical advantages for cell growth or cell transportation, tissue engineering or 3D printing, for example.
Jos Olijve, principal scientist and R&D project manager at Rousselot, will provide a detailed insight at a free-to-access seminar entitled “Endotoxin-Purified Gelatin for Sensitive In-Body and Regenerative Medicine Applications” on Oct. 9 at 15:30 at the bioLIVE Insights Theatre. The presentation will give an overview of the current and potential uses of gelatin in (bio)medical applications and provides examples of the importance of using gelatins with low endotoxin levels.
On Oct. 10 at 12:30 PM, a lunch briefing will also be held entitled “The Importance of Gelatin and its Endotoxin Level for Applications in Regenerative Medicine” at the Content Dome on the show floor to be presented by Prof. Sander Leewenburgh from Radboud University followed by Marit van der Heijden, global marketing manager, Rousselot.
On Oct. 10 the Peptan team will host delegates in meeting room #12.6 at the Finished Dosage Form area, where Peptan experts will be available for one-to-one meetings to discuss joint health supplements needs and strategies to capitalize on current joint health market trends with the new low-dosage hydrolyzed collagen type II matrix.
Peptan IIm is a natural extract containing the matrix elements similar in human cartilage-hydrolyzed collagen type II and glycosaminoglycans-in one single ingredient. The bioactive joint health ingredient offers multiple benefits and is critical for sustaining healthy joints. It has demonstrated that it promotes maintenance of healthy cartilage and improves joint movement by providing cushioning and lubrication as well as by reducing the effects of inflammation, the company reports.
A presentation on Peptan IIm will be held on Oct. 10 at 12:00 PM, hosted by Lisette Van Lith, global director at Peptan, and Dr. Sara Pelsmaeker, product and business development manager.
CPhI Worldwide runs from Oct. 9–11 in Madrid, Spain.